Join Us

We are 218,012 members in 84 forums discussing 160,846 topics.

Help with Abbreviations

Topic: Hormone therapy

Forum: HER2+ (Positive) Breast Cancer —

Testing, treatment, side effects, and more.

Posted on: Sep 19, 2020 10:37AM

windgirl wrote:

Hi, I’m tripple positive and am so upset that there is no information on how recurrence risk is affected by hormonal therapy (and length) for this type of tumor. How is it that there is no studies that have looked at this? What am I missing? how do you all deal with the lack of information in trying to make important decisions

Dx 7/14/2014, IDC, 3cm, Grade 2, 0/3 nodes, ER+/PR+, HER2+ Targeted Therapy 8/13/2014 Herceptin (trastuzumab) Targeted Therapy 8/13/2014 Perjeta (pertuzumab) Chemotherapy 8/13/2014 Carboplatin (Paraplatin), Taxotere (docetaxel) Surgery 12/19/2014 Lumpectomy: Left; Lymph node removal: Left, Sentinel Radiation Therapy 1/28/2015 Breast
Log in to post a reply

Page 1 of 1 (5 results)

Posts 1 - 5 (5 total)

Log in to post a reply

Sep 19, 2020 10:59AM ElaineTherese wrote:

Hi windgirl!

Why don't you use this tool?

https://breast.predict.nhs.uk/

Remember that it's asking you for tumor size in millimeters, so for you that would be 30. You received 3rd generation chemo, and Herceptin (trastuzumab), so be sure to enter that.

When I enter my information, and I select Chart, it says:

"All of the below plus trastuzumab brings survival to 89% at 5 years.

All of the below plus chemotherapy brings survival to 85% at 5 years.

Hormone therapy brings survival to 78% at 5 years.

Surgery only survival is 70% at 5 years"

So, hormone therapy increased my survival rate by 8%.

Hope this helps!

DX IDC June 28, 2014, 5 cm., 1 node tested positive (fine needle biopsy); 0/20 after neoadjuvant chemo + ALND; Grade 3; ER+ PR+ HER2+ Neoadjuvant chemotherapy starting 7/23/14 ACX 4, Taxol X 12, Perjeta X 4; Herceptin: one year Chemotherapy 7/23/2014 AC Targeted Therapy 9/17/2014 Perjeta (pertuzumab) Targeted Therapy 9/17/2014 Herceptin (trastuzumab) Chemotherapy 9/17/2014 Taxol (paclitaxel) Surgery 1/12/2015 Lumpectomy: Right; Lymph node removal: Right, Underarm/Axillary Hormonal Therapy 2/25/2015 Aromasin (exemestane), Zoladex (goserelin) Radiation Therapy 3/9/2015 Breast, Lymph nodes
Log in to post a reply

Sep 19, 2020 12:42PM MinusTwo wrote:

windgirl - as HER2+ you will most likely have chemo before anything else. That seems to be the protocol since it's so fast moving & most MOs seem to focus on that first. There are really lots of threads on here that discuss triple positive, maybe not just stated that way. If I remember correctly ER/PR positive is the most prevalent type of BC, so it you start reading HER2+ threads I think you'll find a good response.

2/15/11 BMX-DCIS 2SNB clear-TEs; 9/15/11-410gummies; 3/20/13 recurrance-5.5cm,mets to lymphs, Stage IIIB IDC ER/PRneg,HER2+; TCH/Perjeta/Neulasta x6; ALND 9/24/13 1/18 nodes 4.5cm; AC chemo 10/30/13 x3; herceptin again; Rads Feb2014
Log in to post a reply

Sep 19, 2020 02:11PM windgirl wrote:

Thank you Elaine! That link seems very helpful. What I am struggling with is recurrence risk and how it’s affected by hormone therapy for us tripple positives. HT is recommended for 10 years because of the Atlas study, which did not separate between her2 status so the benefit of extending HT for tripple positives is not for certain. I am at the 5 year mark and cannot find any meaningful studies that show this for tripple positives

Dx 7/14/2014, IDC, 3cm, Grade 2, 0/3 nodes, ER+/PR+, HER2+ Targeted Therapy 8/13/2014 Herceptin (trastuzumab) Targeted Therapy 8/13/2014 Perjeta (pertuzumab) Chemotherapy 8/13/2014 Carboplatin (Paraplatin), Taxotere (docetaxel) Surgery 12/19/2014 Lumpectomy: Left; Lymph node removal: Left, Sentinel Radiation Therapy 1/28/2015 Breast
Log in to post a reply

Sep 19, 2020 02:13PM windgirl wrote:

Minustwo thanks so much, yes I got chemo surgery and radiation and have been on Tamoxifen for 5.5 years. I am trying to find information that would support me to extend this to 10 years or not, but cannot find anything. My doctor doesn’t know of any either as the key studies on this topic did not pay attention to her2 status.

Dx 7/14/2014, IDC, 3cm, Grade 2, 0/3 nodes, ER+/PR+, HER2+ Targeted Therapy 8/13/2014 Herceptin (trastuzumab) Targeted Therapy 8/13/2014 Perjeta (pertuzumab) Chemotherapy 8/13/2014 Carboplatin (Paraplatin), Taxotere (docetaxel) Surgery 12/19/2014 Lumpectomy: Left; Lymph node removal: Left, Sentinel Radiation Therapy 1/28/2015 Breast
Log in to post a reply

Sep 19, 2020 03:35PM Beesie wrote:

I'm an old-timer around here. I remember years ago digging into Tamoxifen studies and wondering why none broke out HER2- versus HER2+. The reason? Because most Tamoxifen studies were started between the mid '80s to mid '90s when the significance of HER2 was not really well understood. Only approx. 20% of invasive breast cancer cases are HER2+ so to include a separate and equal HER2+ arm in any Tamoxifen study, the sample size (i.e. number of participants) would have needed to be increased, which in turn would increase the cost of the study.

Every researcher has to choose which variables they will break out as separate study arms - HER2 just didn't make the cut back 30 years ago. Clearly a mistake, in hindsight, but they didn't know at the time.

“No power so effectually robs the mind of all its powers of acting and reasoning as fear.” Edmund Burke

Page 1 of 1 (5 results)